Abnormalities of choline processing in cancer cells have been used as a basis for imaging of cancer with positron emission tomography and magnetic resonance spectroscopy. In this study, the transport mechanism for choline was investigated in cultured PC-3 prostate cancer cells. Furthermore, tritiated hemicholinium 3 (HC-3), a well-known inhibitor of choline transport, was studied as a prototypic molecular imaging probe in PC-3 cells and 9L glioma-bearing rats. [ 3 H]Choline uptake by PC-3 cells was found to have both facilitative and nonfacilitative components. Facilitative transport was characterized by partial sodium dependence and intermediate affinity (K M 5 9.7 6 0.8 mM). HC-3 inhibited choline with a K I of 10.56 2.2 mM. Ouabain (1 mM) caused a 94% reduction in choline uptake. At physiologic choline concentration, phosphocholine was the rapid and predominant metabolic fate. The binding of [ 3 H]HC-3 to PC-3 cells was rapid and specific (competitively blocked with unlabeled HC-3). Biodistribution of [ 3 H]HC-3 in 9L gliomabearing rats showed the ranking of uptake to be kidney . lung . tumor . liver . skeletal muscle < blood . brain. In comparison with [ 14 C]choline, [ 3 H]HC-3 showed over twofold higher tumor uptake and favorable uptake ratios of tumor to blood, tumor to muscle, tumor to lung, and tumor to liver. The data demonstrate the quantitative importance of an intermediate-affinity, partially sodium-dependent choline transport system on choline processing in PC-3 cancer cells. The biodistribution properties of [ 3 H]HC-3 in tumor-bearing rats encourage the development of molecular imaging probes based on choline transporter binding ligands.
A LTERATIONS IN CHOLINE METABOLISM have come to be recognized as hallmarks of malignancy. 1 Consequently, intense interest has been given to the development of imaging techniques that evaluate choline processing for the purposes of cancer diagnosis, 1-6 staging, [7] [8] [9] and therapy monitoring. 1, 2, 10, 11 Owing to their capabilities to evaluate metabolic processes, positron emission tomography (PET) and magnetic resonance spectroscopy (MRS) are the predominant modalities used for noninvasive imaging of choline metabolism. MRS studies of biopsied cancerous tissues and MRS imaging of in vivo tumors have generally shown elevated levels of choline-containing metabolites in cancer relative to normal tissue. 1, 3, 4, [10] [11] [12] [13] [14] [15] [16] Of these cholinecontaining metabolites, phosphocholine (PCho) has been found to most closely correlate with malignant transformation, 12, 13 tumor growth rate, 14 metastatic potential, 15 and therapeutic response. 1, 16 Tracer kinetic studies have shown that enhanced choline transport may play a role in the elevation of PCho levels in malignant cells. [17] [18] [19] [20] High intracellular PCho to choline concentration ratios 17 indicate that choline kinase activity levels exceed those needed to supply PCho for phosphatidylcholine synthesis along the Kennedy pathway. 21 Indeed, metabolism of PCho to cytidine diphosphate (CDP)choline, catalyzed by cytidine 59-triphosphate (CTP):PCho cytidylyltransferase, appears to remain highly regulated in tumors. 21 PET studies with 11 C-and 18 F-labeled choline analogues have shown rapid clearance of radiolabeled choline from the blood owing to avid transport activity in kidney and liver. 2, 7 Following bolus intravenous administrations, arterial blood concentrations of choline tracers fall to a few percent of peak values as early as 2 minutes after injection. Despite rapid blood clearance, choline tracer accumulations in several types of primary and metastatic tumors are moderate to high, 2, 5, [7] [8] [9] 22 implying sufficient perfusion and choline transporter activity to support accumulation of tracer in the tumors. Furthermore, analysis of 18 F-labeled metabolites in cultured prostate cancer cells after a 2-hour incubation with [ 18 F]fluorocholine (FCH) showed the radiolabel to be predominantly in the form of phosphorylated FCH, 22 indicating transport and phosphorylation to be important steps for FCH accumulation in prostate cancer cells.
Although there is growing evidence of the importance of choline transport in tumor choline processing, the nature and properties of the choline transporter(s) in the cell membrane of cancer cells are relatively poorly understood. Much work has been performed to genetically identify and clone the choline transporters present in brain, 23 liver, 24 kidney, 25 fibroblasts, 26 and various peripheral tissues, 27 but there are currently only limited data on the choline transport process in tumor cells. [28] [29] [30] [31] [32] [33] [34] [35] Preliminary transport kinetic measurements in several human cancer cell lines showed a range of Michaelis constant (K M ) values (1-60 mM) for choline [28] [29] [30] [31] [32] [33] [34] [35] that was in the same range as physiologic concentrations of choline in plasma (5-50 mM), 27 with most values falling between the neuronal high-affinity process (hCHT1) and the lower-affinity human choline transporter-like protein (hCTL) 1 and human organic cation transporter (hOCT) family of transporters present in peripheral tissues. To our knowledge, the choline transporter has not been characterized in prostate cancer.
In the present study, we performed mechanistic studies on the transport of choline in the PC-3 human prostate cancer cell line to provide further clarification of the properties of the choline transporter. We also propose, for the first time, the use of a radiolabeled analogue of the high-affinity choline transport inhibitor hemicholinium 3 (HC-3) as a molecular imaging probe for the choline transporter in cancer. HC-3 potently inhibits the neuronal high-affinity choline uptake system (CHT1) with enzyme inhibition constant (K I ) 5 0.02 mM 23 and is also a weaker inhibitor of choline kinase (K I 5 500 mM). 36 Cellular binding of [ 3 H]HC-3 is studied in PC-3 cells, whereas its in vivo biodistribution properties are evaluated in a 9L glioma-bearing rat model. The results demonstrate the importance of the transport step for choline processing in PC-3 human prostate cancer cells. Favorable tumor cell binding and biodistribution properties are found for the tritiated form of HC-3, encouraging further characterization and development of molecular imaging agents that target the choline transporter in cancer cells. 
Methods

Purification of Commercially
Kinetics of Choline Transport in PC-3 Cells In Vitro
The PC-3 androgen-independent human prostate cancer cell line was chosen for characterization of the choline transport process because of its widespread availability and use and because it has served as a primary screening tool for development of imaging probes for prostate cancer. PC-3 cells (0.5 3 10 6 cells) were added to 2 mL of Roswell Park Memorial Institute (RPMI) 1640 + 10% fetal bovine serum (FBS) medium contained in 3.7 cm wells and grown under 5% CO 2 for 48 hours. The uptake study was performed after replacing the medium with the uptake medium (20 mM HEPES/Tris buffer, pH 7.4, 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl 2 , 1 mM MgCl 2 , and 10 mM glucose), by incubating the cells with 5 to 500 mM choline (containing [ 3 H]choline) at 37uC for 10 minutes. The uptake reaction was stopped by addition of ice-cold phosphate-buffered saline (PBS), followed by washing with ice-cold PBS three times. The sodium dependence of the uptake was examined by using the uptake medium containing 141 mM LiCl instead of 141 mM NaCl. In all cases, the tracer uptake period followed a 5-minute preincubation with medium lacking [ 3 H]choline to allow for stabilization of the cells in the test medium. The effects of choline transport inhibitor HC-3 (10-100 mM as bromide salt; Sigma-Aldrich, St. Louis, MO) and metabolic inhibitors, ouabain (0.1-1.0 mM; Sigma-Aldrich) and dinitrophenol (0.1 hemicholinium-3 1.0 mM; Sigma-Aldrich), were tested by adding the inhibitors to the incubation medium during the preincubation and [ 3 H]choline incubation periods. The radioactivity was measured by liquid scintillation counting. Total protein content in the cells was determined by the Lowry method. Five wells were used for calculation of each value.
For estimation of the cell to medium radioactivity concentration ratio, cell volume was measured by the hematocrit method using condensed cell suspensions. Approximately 10 mL of well-mixed cell suspension was used to fill a Mylarwrapped, 75 mm hematocrit capillary tube (Drummond Scientific Company, Broomall, PA). The tube was then sealed with plaster and centrifuged at 1,100 rpm for 5 minutes at 4uC. The cell volume was calculated as the quotient of the hematocrit value and the known concentration of cells in the suspension. Using this methodology, 10 6 PC-3 cells were found to occupy a volume of 5.5 mL. Assuming a constant PC-3 cell volume for the entire study, the volume of cells in each incubation well was calculated as the product of 5.5 mL and the number of million cells per well. The cell to medium ratio was calculated as where CPM is counts/minute of radioactivity.
The numerator of Equation 1 represents the radioactivity concentration in the cells, whereas the denominator represents radioactivity concentration in the uptake medium during the uptake period.
Preliminary experiments were done to show that cellular uptake of [ 3 H]choline was linear with time over the first 20 minutes of incubation. Thus, the uptake rate (velocity) was determined as the choline uptake at 10 minutes divided by 10. The uptake rate was then fit by a nonlinear least-squares curve fitting technique 37 to the following equation including a nonfacilitative diffusion term:
where [S] (mM) is choline concentration, [I] (mM) is HC-3 concentration, V max (nmol/mg protein/min) and K M (mM) are the Michaelis-Menten constants for maximal transport velocity and concentration at half-maximal velocity, respectively, K I (mM) is the inhibition constant for HC-3, and D (mL/mg protein/min) is the diffusion coefficient for nonfacilitative diffusion. The model assumes Michealis-Menten kinetics, competitive inhibition by HC-3 at the choline transporter, 32 and first-order diffusion kinetics for the nonfacilitative diffusion component. The r 2 statistic was used as a test of goodness of fit:
where y i is the measured uptake rate, y is the mean uptake rate; andŷ 1 is the model-predicted uptake rate at the ith measurement.
Analytic Method for Choline and Metabolites
Metabolism of [ 3 H]choline in PC-3 cells was analyzed as follows: After the cells were washed three times with icecold PBS, the metabolism was stopped by the addition of methanol, and then hydrophilic and lipophilic compounds were separated by water-methanol-chloroform extraction according to Folch and colleagues. 38 Quantitation of hydrophilic compounds (choline, betaine, phosphorylcholine, CDP-choline, and glycerophosphorylcholine) was performed by a high-performance liquid chromatography-mass spectrometry system (Varian, Palo Alto, CA) using a silica gel column and gradient elution according to the method of Koc and colleagues. 39 The retention time of authentic standards of the choline metabolites was determined using mass spectroscopy with electrospray ionization. For measurements of 3 H-labeled metabolites, fractions of eluant were collected every 30 seconds and counted in a liquid scintillation counter.
Binding of [ 3 H]HC-3 to PC-3 Cells In Vitro
The binding of the radiolabeled choline transporter inhibitor [N-methyl-3 H]HC-3 ( Figure 1 ) (Perkin Elmer Life Sciences) to PC-3 cells was examined in vitro by adding 2 mCi of [ 3 H]HC-3 (specific activity . 120 mCi/nmol) to each well that contained 0.56 3 10 6 cells in 1 mL of uptake buffer. The final concentration of HC-3 in the well was , 15 mM. The cell volume measured by the hematocrit method was 4.26 mL/well. The protein content was 0.33 mg/well. After incubation at 37uC for 10 and 60 minutes, cells were quickly washed once with 3 mL of PBS. The binding of [ 3 H]HC-3 was expressed by cell to medium ratio. In a second group, cells were preincubated with 100 mM nonradioactive HC-3 for 5 minutes, and then 2 mCi of [ 3 H]HC-3 was added. 
Biodistribution of [ 3 H]HC-3 and [Methyl-14 C]Choline in 9L Glioma-Bearing Rats
To understand the in vivo disposition of HC-3 in a tumorbearing animal model, the biodistribution of [ 3 H]HC-3 was investigated in Fischer 344 rats (n 5 5) bearing subcutaneous 9L gliomas. We chose against using a PC-3 xenograft mouse model for this study because a rat model would allow for more practical collection of arterial blood samples and previous work with the PC-3 xenografts showed low accumulations of choline radiotracers indicative of poor perfusion of these tumors. 7 Since elevation of choline uptake is found in a wide variety of tumors, including gliomas, 19, 35 the model serves as a representative model for evaluating choline-based imaging probes. For comparison with tracer choline behavior, a separate group of rats (n 5 8) was similarly studied with [methyl-14 C]choline. The radiotracers (<300 KBq) were administered as an intravenous bolus to a tail vein, and the animal was euthanized at 20 minutes postinjection. Prior to injection, the carotid artery was cannulated and arterial blood samples were collected over the duration of the experiment. After euthanization, the major tissues and organs were dissected, weighed, digested (SOLVABLE, Perkin-Elmer Life Sciences), and counted for 3 H-or 14 Cradioactivity in a liquid scintillation counter. Uptake in each tissue was expressed as a percentage of the injected dose per gram of tissue.
Statistical Methods
Values are expressed as mean 6 SD. The statistical significance of differences of tracer uptakes in PC-3 cells with different conditions was determined by Student's ttest, with p , .05 considered significant. Differences in biodistribution uptake values between different tracers were treated likewise.
Results
Kinetics of Choline Transport in PC-3 Cells In Vitro
The dependence of [ 3 H]choline uptake by PC-3 cells on choline concentration is shown in Figure 2 . The uptake velocity into the cells was fit to a Michaelis-Menten model that included both facilitative and nonfacilitative diffusion transport terms (Equation 2). The facilitative component showed intermediate affinity (K M 5 9.7 6 0.8 mM) (Table  1) . Transport by nonfacilitative diffusion was also evident and became dominant at choline concentrations greater than 200 mM. Facilitative transport was maintained after replacement of sodium ions with lithium ions in the culture medium. Although V max was unchanged, the K M value increased to 28.2 6 2.7 mM, indicating that the uptake mechanism was partially sodium dependent (see Figure 2 ). The effect of HC-3, a potent inhibitor of choline transporter in the brain (CHT1) (K I , <0.02 mM) 23 and an inhibitor of choline kinase (K I , <500 mM), 36 on the choline uptake was examined. The cell culture conditions were the same as above. HC-3 inhibited transporterfacilitated choline uptake in a concentration-dependent fashion (K I 5 10.5 6 2.2 mM) but did not inhibit free diffusion at higher concentrations of choline (see Table 1 and Table 1. r 2 values of near-unity (see Table 1 ) that indicated excellent goodness of fit. The resultant K I suggested that the potency of HC-3 to inhibit choline transport in PC-3 cells is intermediate between the higher potency described for hCHT1 inhibition (<1 mM) and the markedly lower potency for hOCT1 or hOCT2 inhibition (<250 mM). 24, 25 To further characterize the mechanism of choline transport, it was of interest to determine the sensitivity of choline transport rates to inhibition of Na/K-dependent adenosine triphosphatase (ATPase) using ouabain (0.1-1 mM) and inhibition of cellular adenosine triphosphate (ATP) production using the oxidative phosphorylation uncoupler dinitrophenol (0.1-1 mM) ( Table 2 ). It was anticipated that a diminishing of the negative membrane potential with ouabain would cause a decrease in choline transport rate because the positively charged choline molecule travels in the same direction as the charge gradient across the cell membrane. A second method used to decrease the membrane potential was replacement of sodium ions with potassium ions in the culture medium (see Table 2 ). Metabolic inhibition with the uncoupler dinitrophenol was anticipated to also decrease cell membrane choline transport, either by decreasing the availability of intracellular ATP needed by an active transport mechanism or by decreased activity of the Na/K-dependent ATPase and the consequent effects of this inhibition mentioned above. PC-3 cells were subject to the inhibitors during a preincubation period of 5 minutes (unless noted otherwise) followed by an incubation period with [ 3 H]choline for 10 minutes. Ouabain inhibited both transporter-facilitated uptake (5 mM choline) and free diffusion (500 mM choline). The inhibition was dependent Table 1 . Solid circles 5 control; empty squares 5 10 mM HC-3; solid triangles 5 50 mM HC-3; empty diamonds 5 100 mM HC-3. on ouabain concentration and was somewhat greater in magnitude at the low concentration of choline. The sensitivity of choline uptake to ouabain is consistent with the inhibition of uptake of positively charged choline molecules as the inwardly directed negative force of the membrane potential is diminished. Choline uptake was also decreased by replacement of sodium ions with potassium ions in the culture medium, although there was a slower onset of this effect than for ouabain: potassium-for-sodium replacement for a 60minute preincubation period resulted in approximately the same level of decrease of choline uptake as 0.1 mM ouabain for a 5-minute preincubation period. Metabolic inhibition with the oxidative phosphorylation uncoupler dinitrophenol resulted in a concentrationdependent decrease in choline uptake, but the differences were relatively smaller than the inhibition with ouabain. These data confirmed the importance of a facilitative transport process for radiolabeled choline uptake into tumor cells that was most sensitively inhibited with a reduction in Na/K-dependent ATPase activity by ouabain.
Uptake and Metabolism of [ 3 H]Choline in PC-3 Cells In Vitro
The time course of [ 3 H]choline uptake was examined after the addition of 5 or 500 mM [ 3 H]choline (Table 3 ). Figure  4 shows the distribution of radioactivity among the most prevalent choline metabolites as a function of incubation time. At low extracellular choline concentration, the intracellular radiolabel was primarily found as [ 3 H]PCho, indicating rapid phosphorylation of transported [ 3 H]choline (see Figure 4 ). The ratio of [ 3 H]PCho to [ 3 H]choline increases from approximately 7 to 24 over the interval of 10 to 60 minutes. At a low extracellular choline concentration of 5 mM, the cell to medium ratio increased from 11.3 6 0.2 at 10 minutes to 39.8 6 1.6, demonstrating the concentration of radiolabeled choline within cells resulting from intracellular phosphorylation. There was significant but minimal (, 4% over 60 minutes) metabolism of PCho to CDP-choline and lipophilic species. No radiolabeled betaine was detected in the cells or in the culture medium. At a high extracellular choline concentration of 500 mM, total choline uptake is approximately 10-fold increased owing to increased levels of nonfacilitative diffusion (see Figure  2 ). In this condition, the fraction of radiolabel found as nonmetabolized choline (<50% at 10 minutes; see Figure Choline Transporter in Cancer 4) is markedly higher and the levels of PCho (<46% at 10 minutes) are correspondingly lower than at a low extracellular choline concentration, demonstrating a flux limitation of choline kinase at the supraphysiologic extracellular choline concentration. The limited capacity of the cells to metabolically concentrate choline was also noted from cell to medium ratios that were approximately 10-fold lower than those at low extracellular choline concentration, as well as 
Binding of [ 3 H]HC-3 to PC-3 Cells In Vitro
The binding of the radiolabeled choline transporter inhibitor [ 3 H]HC-3 to PC-3 cells was examined in vitro. The cell to medium ratio was 3.64 6 0.49 after 10 minutes of incubation and did not change after 60 minutes of incubation (3.67 6 0.33). This suggested that a binding equilibrium had been reached within 10 minutes. To determine the saturability of the binding process, [ 3 H]HC-3 binding was evaluated in the presence of nonradioactive HC-3 (100 mM). The cell to medium-ratio at 10 minutes of incubation was reduced to 0.72 6 0.19 (p , .001) in the presence of unlabeled HC-3, demonstrating saturability of binding. The cell to medium ratio was lower for [ 3 H]HC-3 than for [ 3 H]choline at all time points (see Table 3 ), consistent with the fact that [ 3 H]HC-3 lacks a metabolical trapping mechanism to concentrate radioactivity in the cells.
Biodistribution of [ 3 H]HC-3 in 9L Glioma-Bearing Rats
Blood clearance of radioactivity was rapid in the first 4 minutes following intravenous injection of [ 3 H]HC-3 in the rat ( Figure 5 ). Slower blood clearance is seen thereafter. The biodistribution data are shown in Table 4 in comparison with data from [ 14 C]choline in the same experimental model. The ranking of uptake was found to be kidney . lung . tumor . atrioventricular node . liver . skeletal muscle < blood. In comparison with [ 14 C]choline, tritiated HC-3 showed over twofold higher tumor uptake (p , .05). The uptake ratios of tumor to blood, tumor to muscle, tumor to lung, tumor to liver, and tumor to kidney were trended higher for [ 3 H]HC-3 relative to [ 14 C]choline, although high intersubject variability precluded statistical significance of the differences. Uptake of HC-3 in the brain was very low, whereas excretion of radioactivity in urine was relatively high.
Discussion
There is currently intense interest in the development of both PET and MRS imaging techniques to differentiate and localize malignancies based on abnormalities of choline processing in cancer cells. The present finding of rapid formation and persistent levels of [ 3 H]PCho in PC-3 prostate cancer cells incubated with [ 3 H]choline confirms the general consensus that is forming among choline imaging researchers that PCho accumulation in a variety of tumor cells is a hallmark of malignancy (recently reviewed in Gillies and Morse 1 ). Elevated PCho levels may result from one or more of the following changes:
1. Increased rate of extracellular choline uptake and phosphorylation by choline kinase 2. Decreased phosphatase activity acting on PCho 3. Decreased rate of metabolism of choline to CDPcholine by CTP to PCho cytidylyltransferase 4. Increased rate of phospholipase C catalyzed breakdown of phosphatidylcholine to PCho and diacylglycerol 5. Increased rate of phospholipase D catalyzed breakdown of phosphatidylcholine to choline and phosphatidic acid, followed by choline phosphorylation by choline kinase 6. Increased breakdown of phosphatidylcholine to choline through successive metabolism by phospholipase A 1 , phospholipase A 2 , and phosphodiesterase, followed by choline phosphorylation by choline kinase 7. Decreased oxidation of intracellular choline to betaine Of the seven factors listed above, only the third can be considered implausible based on evidence showing that CTP to PCho cytidylyltransferase activity is tightly regulated to maintain membrane homeostasis. 40, 41 The last factor regarding decreased choline oxidation may be relevant only if the normal tissue from which the tumor originated has significant levels of mitochondrial choline dehydrogenase and betaine aldehyde dehydrogenase, as would be the case for hepatocellular and renal carcinomas. The remaining five factors are considered to be plausible explanations for elevated PCho levels in neoplasms. Detailed tracer kinetic studies in breast cancer 17, 18, 20 and MRS studies in glioma cells 19 indicate that the majority of accumulated PCho in cancer cells is derived from extracellular choline followed by phosphorylation. Also, a number of studies show a significant contribution of phospholipases to the elevation of PCho levels in cancer cells. 1, [42] [43] [44] Although phospholipid turnover rates were not measured in the present study in PC-3 prostate cancer cells, the rapid accumulation of [ 3 H]PCho following incubation with [ 3 H]choline also suggests the importance of uptake and phosphorylation. An increase in the extracellular choline concentration from 5 to 500 mM resulted in a 10-fold increase in total [ 3 H]choline uptake by the cells, whereas the [ 3 H]PCho contribution increased approximately 4-fold at the earliest measurement point of 10 minutes (see Table 3 ). At the same time point, the majority of the increased total [ 3 H]choline uptake was in the form of nonmetabolized tracer (see Figure 4 ) that was presumably retained within the cytoplasm by virtue of its positive charge in the presence of a negative membrane potential. This fraction was largely phosphorylated over the following hour but at a much slower rate than at 5 mM extracellular choline concentration. Thus, choline phosphorylation increased dramatically as the extracellular choline concentration was raised, yet there was an even greater enhancement of choline transport attributable to increased rate of transport by nonfacilitative diffusion (see Figure 2 ). From our data, the contribution of nonfacilitative diffusion to the overall transport rate is indicated to be minor (, 25%) at physiologic concentrations of choline in the plasma (5-50 mM).
Rather, choline transport rates in vivo would be expected to be governed by plasma choline levels, diffusion in the extracellular space, and expression and activity of the choline transporter(s). Importantly, this study demonstrates that at physiologic plasma choline concentrations, the capacity of choline kinase to phosphorylate choline was several-fold higher than the transport rate. Transport was a rate-determining step for tracer choline accumulation in the cells. Katz-Brull and colleagues estimated that the rate of choline phosphorylation was more than two orders of magnitude faster than the rate of its transport in cultured breast cancer cells, maintaining the ratio of concentrations of PCho to choline higher than 100. 18 The significance of the role of choline transport also follows from the success of PET imaging of various cancers with 11 C-and 18 F-labeled cholines despite an extremely rapid blood clearance of tracer (, 2 minutes). 2, [5] [6] [7] 22 We previously noted that the adequacy of uptake of FCH to allow visualization in PET images of primary and metastatic prostate cancer tumors in the presence of rapid blood clearance of tracer suggests a high dependence of tumor uptake on tumor perfusion and efficient transport from the blood into tumor cells. 7 Intracellular phosphorylation is unlikely to be rate determining, although it plays an essential role in sequestering the PET choline tracers in the cell to provide high tumor to normal tissue contrast for imaging purposes. The radioactivity concentration in tumor at later times (. 10 minutes postinjection) may reflect intracellular metabolic events. For example, it has been speculated that the maintenance of radioactivity concentration in primary prostatic tumors in the presence of a slow clearance of radioactivity in neighboring normal prostate tissue may reflect lower prostatic phosphatase activity in tumor. 5 Given the influence of the choline transporter(s) in tumor processing of choline and the important role it therefore plays in diagnostic imaging studies of choline metabolism with MRS and PET, there is an obvious need to identify and characterize this transporter in human neoplasms. Yet very little is known about the choline transporter(s) in human tumors. From the scant literature data available, [28] [29] [30] [31] [32] [33] [34] [35] there may be significant differences in the transport characteristics in various tumor cell lines. The present study indicates that choline enters PC-3 prostate cancer cells via a carrier-mediated mechanism since it fulfills a number of well-established criteria. 45 Choline transport in PC-3 cells has a saturable, facilitative component apparent at low extracellular choline concentrations (, 50 mM) and a nonfacilitative diffusion component that becomes quantitatively important only at higher choline concentrations (. 50 mM). The facilitative transport system has the characteristics of intermediate affinity (K M <10 mM) and partial sodium dependence, distinguishing it from the high-affinity, sodium-dependent system of the central nervous system (hCHT1) and the low-affinity, sodium-independent systems (hOCTs) in liver and kidney. There are substantial differences reported in the K M values for choline transport in various cancer cell lines, although, in general, the K M values are intermediate between those of hCHT1 and the hOCT family of transporters. The potency of HC-3 to inhibit choline uptake may also serve as a means to functionally characterize the transporter. HC-3 inhibits choline transport in PC-3 cells (K I < 10 mM), with a substantially higher potency than for choline transport in Krebs II ascites cells (K I 5 160 mM). HC-3's potency in PC-3 cells stands between that for hCHT1 and the hOCT family. 24, 25 Choline transport is further characterized with respect to its sensitivity to inhibitors. In our study, we followed the approach Ribbes and colleagues used to characterize choline transport in Krebs II ascites cells. 31 As found for ascites cells, ouabain, an inhibitor of Na/K-dependent ATPase, caused a concentration-dependent reduction in choline accumulation in the PC-3 cells. Our interpretation of this effect is that reductions in the amplitude of the negative membrane potential caused by ouabain results in decreased influx (via facilitative transport and nonfacilitative diffusion) and/or increased efflux of choline cations from the cell. Replacement of sodium with potassium caused modest reductions in choline accumulation in PC-3 cells, consistent with previous findings in Krebs II ascites cells. 31 However, dinitrophenol, an oxidative phosphorylation uncoupler, caused modest reductions in choline uptake in our PC-3 cells but no change in ascites cells. 31 As a whole, the data show that at physiologic concentrations of extracellular choline, the choline transport process in PC-3 cells is dominated by a carrier-mediated mechanism. The kinetic properties of the choline transporter(s) in PC-3 cells are distinct from those on neurons (hCHT1) and the known hOCT family of polyspecific organic cation transporters in liver and kidney. There are a number of similarities of characteristics of the choline transporter(s) in PC-3 cells with what is known of a newly discovered family of choline transporter-like (CTL) proteins (hCTL1-5) present in a variety of human tissues. 27 More extensive molecular and functional characterization studies have been done with CTL transporters in mice and rats, 27 showing CTL transporters to be sodium-independent (although there is some disagreement in the literature regarding the sodium dependency of hCTL), intermediateaffinity transporters of choline that can be completely inhibited by HC-3. Clearly, further work is required to genetically identify and characterize the choline transporter(s) in human cancers. As a first step, it will be important to evaluate the transport mechanism(s) in an androgen-sensitive prostate cancer cell line, such as LNCaP.
Given the important role of the choline transporter(s) in certain tumors, we proposed to develop molecular imaging probes that bind to the choline transporter(s) as potential tumor imaging agents for single-photon emission computed tomography (SPECT) or PET. It is anticipated that a noninvasive method of monitoring the expression and membrane presentation of the choline transporter(s) could be developed with an appropriate probe and corresponding imaging system. To test the feasibility of this approach, experiments were first performed with commercially available [ 3 H]HC-3. HC-3 is a commonly employed high-affinity inhibitor of sodium-dependent choline transport of cholinergic neurons in the central nervous system (hCHT1). Its potency is dramatically lower for inhibition of hOCT family-mediated choline transport in the liver and kidney. 24, 25 Previous studies in our laboratory showed that 18 F-labeled choline uptake by PC-3 cells was 90% blocked by the addition of HC-3 in the culture medium, demonstrating a significant interaction of HC-3 with the choline transporter(s). 7 In the same study, HC-3 had no effect on uptake of the glucose analogue fluorodeoxyglucose ([ 18 F]FDG), demonstrating specificity of its action. Our preliminary experiments in cultured PC-3 cells demonstrated rapid binding of [ 3 H]HC-3 that competed with unlabeled HC-3. An equilibrium was reached within 10 minutes of incubation. The lack of increase over the subsequent hour indicates that there is negligible cellular accumulation, at least within this time frame. Because of its bisquarternary structure, HC-3 is a highly polar molecule that would be expected to have slow diffusion across cell membranes. Although HC-3 has been shown to weakly inhibit choline kinase in in vitro enzyme assays, 36 its ability to dramatically lower PCho levels in cultured cancer cells 36 or xenografts following administration in host animals 36 may result from inhibition of choline transport in addition to potential effects on choline kinase activity. The much greater potency of HC-3 for inhibition of transport (K I <10 mM) relative to choline kinase (K I <500 mM) and the limitation of HC-3 permeation into cells argue for the mechanism of action being primarily at the transport step.
The biodistribution study in the 9L glioma-bearing Fischer rat model demonstrated moderate uptake of [ 3 H]HC-3 in tumor and a mean tumor to blood concentration ratio of 4.6 at 20 minutes postinjection. Tumor uptake was significantly higher for [ 3 H]HC-3 than for [ 14 C]choline in the same model. The organs with highest uptake for both radiotracers were the liver and kidney. However, the normal uptake in the liver with [ 3 H]HC-3 was approximately one-tenth that of [ 14 C]choline. If a similar relationship is found in humans, positron-labeled HC-3 analogues may have a distinct advantage over radiolabeled choline analogues for evaluating liver lesions with PET. Liver lesions are not common with prostate cancer; they are more relevant to other cancer types, including breast cancer, colorectal cancers, and hepatocellular carcinoma. The higher hepatic accumulation of [ 14 C]choline is likely due to its concentration in tissue through metabolic sequestration in the cells. [ 3 H]HC-3 presumably lacks this property. The higher urinary excretion of [ 3 H]HC-3 points to a potential disadvantage of a SPECT or PET probe of prostate cancer imaging based on HC-3, but the confounding of images by urinary radioactivity can be minimized by hydration of the patient prior to injection and voiding of the bladder prior to the commencement of the radiologic scan. This is a common practice in many PET centers for evaluation of pelvic tumors using the highly excreted glucose analogue
The biodistribution data corroborated previous work by Domino and colleagues, who performed whole-body autoradiography of mice at 10 minutes after intravenous administration of [methyl-14 C]HC-3. 46 In their study, the highest radioactivity concentrations in the whole body were found in the solar plexus and bone marrow, organs not sampled in our study. The solar plexus (celiac plexus) is a great cluster of autonomic nerve ganglia located behind the stomach and contains a high density of presynaptic high-affinity choline transporters. Low accumulation of radioactivity in the brain (also rich in highaffinity choline transporters) indicates minimal transport of radiolabeled HC-3 across the blood-brain barrier. The high radioactivity in the bone marrow in the vertebrae and in the ribs represented the high uptake of [ 14 C]HC-3 in rapidly proliferating hematopoietic cells. It will be important to follow up these observations in tumorbearing animal studies of other cancer types, including prostate cancer and breast cancer.
These data support a novel approach to development of molecular imaging probes for cancer based on binding of an HC-3 analogue (or another choline transporter binding molecule) to the choline transporter(s). The chemical structure of HC-3 is amenable to labeling of its biphenyl moiety with radiohalogens or radiometal chelator conjugates for SPECT or PET, whereas the quarternary ammonium groups can be labeled with 11 C-methyl or 18 F-methyl groups for PET. Labeling with optically active dyes could also be explored for use with optical imaging modalities. The potential for changes in the biochemical behavior caused by the addition of a different labeling group must be considered in designing and evaluating new HC-3 analogue tracers. Furthermore, the potential for mass effects at saturable choline transporter target sites and toxicity will place minimum limits on acceptable specific activities for the tracers. HC-3 has a median lethal dose of 0.12 mg/kg in mice, although slightly higher toxicities were seen with several HC-3 structural analogues. 47 Because of the high imaging sensitivity of PET, the mass levels associated with administration of PET probes (on the order of 1 mg per dose) will be much less than these indicated toxicity levels. Our laboratory is now developing 11 C-and 18 F-labeled derivatives of HC-3 for evaluation as PET agents.
Conclusion
The facilitative transport system for choline in cultured PC-3 human prostate cancer cells was characterized by intermediate affinity (K M 5 9.7 6 0.8 mM), partial sodium dependence, and an intermediate inhibition potency of HC-3 (K I 5 10.5 6 2.2 mM). These characteristics distinguish it from the neuronal high-affinity, sodiumdependent choline transport system (hCHT1) and the lowaffinity, sodium-independent choline transport systems (hOCT family) present in non-neuronal tissues such as the kidney and liver. Further work is needed to characterize the choline transport system in each tumor type and determine its possible relatedness to the newly discovered hCTL family of intermediate-affinity, sodium-independent choline transporters. 20 The high dependence of choline processing in tumors on the transport process suggests the choline transporter(s) as a novel target for molecular imaging. Preliminary evaluation studies of the in vivo distribution of the choline transport inhibitor [ 3 H]HC-3 in a 9L glioma-bearing rat model demonstrated significant binding of the radiotracer in tumor and favorable tumor to muscle ratios. The results anticipate the development of a variety of appropriately labeled analogues of HC-3 (or other choline transporter binding molecules) as molecular probes for noninvasive imaging of choline transporter(s) in tumors using a variety of available molecular imaging modalities.
